BR112022019554A2 - Método e composição farmacêutica para tratar uma infecção viral por ácido ribonucleico, e, uso de um composto - Google Patents

Método e composição farmacêutica para tratar uma infecção viral por ácido ribonucleico, e, uso de um composto

Info

Publication number
BR112022019554A2
BR112022019554A2 BR112022019554A BR112022019554A BR112022019554A2 BR 112022019554 A2 BR112022019554 A2 BR 112022019554A2 BR 112022019554 A BR112022019554 A BR 112022019554A BR 112022019554 A BR112022019554 A BR 112022019554A BR 112022019554 A2 BR112022019554 A2 BR 112022019554A2
Authority
BR
Brazil
Prior art keywords
compound
viral infection
pharmaceutical composition
ribonucleic acid
treat
Prior art date
Application number
BR112022019554A
Other languages
English (en)
Inventor
Soong Tai-Sen
Original Assignee
Senhwa Biosciences Inc
Tai Sen Soong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences Inc, Tai Sen Soong filed Critical Senhwa Biosciences Inc
Publication of BR112022019554A2 publication Critical patent/BR112022019554A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

MÉTODO E COMPOSIÇÃO FARMACÊUTICA PARA TRATAR UMA INFECÇÃO VIRAL POR ÁCIDO RIBONUCLEICO, E, USO DE UM COMPOSTO. A presente invenção provê um composto ou um método para tratar uma infecção viral por RNA em um humano, particularmente COVID-19. O composto é um certo composto tricíclico.
BR112022019554A 2020-03-30 2021-03-18 Método e composição farmacêutica para tratar uma infecção viral por ácido ribonucleico, e, uso de um composto BR112022019554A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063001723P 2020-03-30 2020-03-30
US202063053908P 2020-07-20 2020-07-20
PCT/US2021/022976 WO2021202114A1 (en) 2020-03-30 2021-03-18 Antiviral compounds and method for treating rna viral infection, particularly covid-19

Publications (1)

Publication Number Publication Date
BR112022019554A2 true BR112022019554A2 (pt) 2022-12-06

Family

ID=77920792

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022019558A BR112022019558A2 (pt) 2020-03-30 2021-03-18 Método para tratar uma infecção por vírus hepatotrópico, composição farmacêutica para tratar uma infecção viral hepatotrópica, e, uso de um composto
BR112022019554A BR112022019554A2 (pt) 2020-03-30 2021-03-18 Método e composição farmacêutica para tratar uma infecção viral por ácido ribonucleico, e, uso de um composto

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112022019558A BR112022019558A2 (pt) 2020-03-30 2021-03-18 Método para tratar uma infecção por vírus hepatotrópico, composição farmacêutica para tratar uma infecção viral hepatotrópica, e, uso de um composto

Country Status (11)

Country Link
US (2) US20210308137A1 (pt)
EP (2) EP4126845A4 (pt)
JP (2) JP2023520883A (pt)
KR (2) KR20230004550A (pt)
CN (1) CN116075502B (pt)
AU (2) AU2021248867A1 (pt)
BR (2) BR112022019558A2 (pt)
CA (2) CA3179167A1 (pt)
IL (2) IL296924A (pt)
TW (2) TW202203914A (pt)
WO (2) WO2021202115A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102641010B1 (ko) 2023-12-04 2024-02-28 대한민국 실미타세르팁을 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002298A (es) * 2006-09-01 2009-06-04 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteina quinasa y de parp.
CN101528704B (zh) * 2006-09-01 2014-04-09 生华生物科技股份有限公司 丝氨酸-苏氨酸蛋白激酶和parp调节剂
MX2010009445A (es) * 2008-02-29 2011-05-25 Cylene Pharmaceuticals Inc Moduladores de proteina kinasa.
CN102481289A (zh) * 2009-04-17 2012-05-30 赛林药物股份有限公司 治疗与蛋白激酶ck2活性有关的疾病的方法
JP2013505252A (ja) * 2009-09-16 2013-02-14 サイリーン ファーマシューティカルズ インコーポレーティッド 三環式タンパク質キナーゼ調節剤
WO2011063398A1 (en) * 2009-11-23 2011-05-26 Cylene Pharamaceuticals, Inc. Polymorphs and salts of a kinase inhibitor
EP2509602B9 (en) * 2009-12-04 2017-11-01 Senhwa Biosciences, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
TWI534148B (zh) * 2014-02-13 2016-05-21 生華生物科技股份有限公司 吡唑並嘧啶前藥及其使用方法
CN105457029A (zh) * 2014-09-29 2016-04-06 中国科学院上海巴斯德研究所 抑制酪蛋白激酶2活性在促进i型干扰素表达的应用
US20230131943A1 (en) * 2020-03-24 2023-04-27 Burnet Micheal W Anti-infective and anti-viral compounds and compositions
WO2021247367A1 (en) * 2020-06-02 2021-12-09 Yale University Compounds and compositions for treating, ameliorating, and/or preventing sars-cov-2 infection and/or complications thereof

Also Published As

Publication number Publication date
AU2021249224A1 (en) 2022-12-01
WO2021202115A1 (en) 2021-10-07
IL296927A (en) 2022-12-01
KR20230004550A (ko) 2023-01-06
TW202203914A (zh) 2022-02-01
WO2021202114A1 (en) 2021-10-07
EP4126845A1 (en) 2023-02-08
KR20230004549A (ko) 2023-01-06
AU2021248867A1 (en) 2022-12-01
CA3179372A1 (en) 2021-10-07
CN116075502B (zh) 2024-04-12
US20210308137A1 (en) 2021-10-07
IL296924A (en) 2022-12-01
EP4126846A1 (en) 2023-02-08
US20210308110A1 (en) 2021-10-07
BR112022019558A2 (pt) 2022-12-06
TW202203915A (zh) 2022-02-01
US11696911B2 (en) 2023-07-11
CN116075502A (zh) 2023-05-05
EP4126845A4 (en) 2024-05-01
CA3179167A1 (en) 2021-10-07
JP2023520882A (ja) 2023-05-22
JP2023520883A (ja) 2023-05-22

Similar Documents

Publication Publication Date Title
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
MX2020010941A (es) Moleculas y composiciones novedosas de arn de vsr para vacunacion.
BR112021024310A2 (pt) Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
BR112022002150A2 (pt) Composições e métodos para tratar psoríase e dermatite atópica com o uso de prevotella histicola
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112021022624A2 (pt) Compostos para o tratamento da doença de huntington
BR112015016293A2 (pt) derivados de benzilamina
BRPI1012219C1 (pt) produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
MX2022011173A (es) Tratamiento de infeccion por coronavirus.
BR112022024120A2 (pt) Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
BR112022020147A2 (pt) Compostos para tratar a doença de huntington
BR112022019554A2 (pt) Método e composição farmacêutica para tratar uma infecção viral por ácido ribonucleico, e, uso de um composto
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
BR112023025916A2 (pt) Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção
BR112022001025A2 (pt) Inibidores de calicreína plasmática
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
BR112022002025A2 (pt) Composições e métodos para tratar águas residuais
BR112022010750A2 (pt) Método para tratar câncer usando célula adjuvante artificial (aavc)
BR112023025986A2 (pt) Compostos úteis no tratamento ou prevenção de um distúrbio mediado por prmt5